Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSE2101 TEDOPI vs docetaxel or pemetrexed in 2nd/3rd-line advanced NSCLC (HLA-A2+)
2015-003183-36Phase 3Completed
- Sponsor
- OSE Immunotherapeutics
- Start
- Nov 2015
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of Tedopi in non-small cell lung cancer (NSCLC) (2 arms), sponsored by OSE Immunotherapeutics. Primary endpoint: Overall survival. Started Nov 2015; status: completed.
02
Drugs
Tedopi
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-003183-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003183-36.